suramin has been researched along with Dysesthesia in 4 studies
Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.
suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ten male patients with onchocerciasis received six weekly infusions of suramin according to the WHO-recommended regimen." | 9.08 | Clinical pharmacokinetics of suramin in patients with onchocerciasis. ( Chijioke, CP; Fleckenstein, LL; Mbah, AU; Nwonu, P; Okonkwo, PO; Umeh, RE, 1998) |
| "Ten male patients with onchocerciasis received six weekly infusions of suramin according to the WHO-recommended regimen." | 5.08 | Clinical pharmacokinetics of suramin in patients with onchocerciasis. ( Chijioke, CP; Fleckenstein, LL; Mbah, AU; Nwonu, P; Okonkwo, PO; Umeh, RE, 1998) |
| "This phase I study was designed with the following objectives: (1) to describe the overall and dose-limiting toxicity (DLT) of suramin administered by intermittent short intravenous infusions until DLT or disease progression; (2) to determine the ability of an adaptive control with feedback (ACF) dosing strategy to maintain suramin plasma concentrations within a preselected range; (3) to develop a population model of suramin pharmacokinetics; and (4) to identify preliminary evidence of antitumor activity." | 2.68 | Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer. ( Eisenberger, MA; Hemady, RK; Jacobs, SC; Jodrell, DI; Lowitt, MH; Reyno, LM; Sinibaldi, VJ; Sridhara, R; Tkaczuk, KH; Zuhowski, EG, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (75.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wise, E | 1 |
| Easom, N | 1 |
| Watson, J | 1 |
| Bailey, R | 1 |
| Brown, M | 1 |
| Eisenberger, MA | 1 |
| Sinibaldi, VJ | 1 |
| Reyno, LM | 1 |
| Sridhara, R | 1 |
| Jodrell, DI | 1 |
| Zuhowski, EG | 1 |
| Tkaczuk, KH | 1 |
| Lowitt, MH | 1 |
| Hemady, RK | 1 |
| Jacobs, SC | 1 |
| Chijioke, CP | 1 |
| Umeh, RE | 1 |
| Mbah, AU | 1 |
| Nwonu, P | 1 |
| Fleckenstein, LL | 1 |
| Okonkwo, PO | 1 |
| La Rocca, RV | 1 |
| Meer, J | 1 |
| Gilliatt, RW | 1 |
| Stein, CA | 1 |
| Cassidy, J | 1 |
| Myers, CE | 1 |
| Dalakas, MC | 1 |
2 trials available for suramin and Dysesthesia
| Article | Year |
|---|---|
Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer.
Topics: Adaptation, Physiological; Aged; Anorexia; Bayes Theorem; Cohort Studies; Drug Monitoring; Drug Resi | 1995 |
Clinical pharmacokinetics of suramin in patients with onchocerciasis.
Topics: Adult; Animals; Antinematodal Agents; Exanthema; Foot; Humans; Hypopigmentation; Male; Metabolic Cle | 1998 |
2 other studies available for suramin and Dysesthesia
| Article | Year |
|---|---|
Lesson of the month: a psychiatric diagnosis overturned by a blood film.
Topics: Antibodies, Protozoan; Cerebrospinal Fluid; Diagnosis, Differential; Female; Humans; Melarsoprol; Me | 2012 |
Suramin-induced polyneuropathy.
Topics: Adult; Cerebrospinal Fluid Proteins; Female; Humans; Male; Middle Aged; Neoplasms; Neural Conduction | 1990 |